...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Statistical Considerations
3
Mar 05, 2018 01:55PM
1
Mar 06, 2018 03:34AM
4
Mar 06, 2018 12:30PM
10
Mar 06, 2018 02:22PM
1
Mar 06, 2018 03:04PM

Mar 07, 2018 10:57AM
1
Mar 07, 2018 01:42PM
3
Mar 07, 2018 04:08PM
4
Mar 07, 2018 07:24PM
2
Mar 08, 2018 07:15AM
3
Mar 08, 2018 09:27AM
1
Mar 08, 2018 12:03PM
2
Mar 08, 2018 02:06PM

Mar 08, 2018 03:47PM

Mar 08, 2018 07:06PM
2
Mar 08, 2018 07:55PM

Hi Bear,

I differently see your viewpoints and that some of my views are conjecture

with your comment below, do you know if any of the other cardivascular outcome trial you mentioned have had any postive results  with 5 point MACE outcome. The Assure trial   had  a 77% RRR in the post hoc analysis   with low hdl patients with Diabetes... so my hope is we can repeat or come close with a 3 point mace outcome.

"  Plenty of recent cardiovascular outcomes trials in diabetes patients have gone to completion and found to have no significant effect to reduce the 3-point MACE primary outcome. In my opinion, a potential interim statistical analysis (i.e. the sample size re-estimation analysis at 75% of planned events = ~188 events"

 

4
Mar 10, 2018 02:04PM
9
Mar 10, 2018 02:34PM
Share
New Message
Please login to post a reply